AURX
insider transactionsNuo Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-66.7K
133.3K buy · 200.0K sell
Net value · 365d
-$100.0K
$200.0K in · $300.0K out
Sentiment · 365d
Net selling
40% buying · 60% selling
Open-market trades · 365d
2
133.3K buy · 200.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Grant·A
CEO/CFO
$14.5K
13.2K sh · $1.10
Own +1%
-
Grant·A
Director, 10% Owner
$63.4K
42.3K sh · $1.50 avg · 3 lots
Own New
-
Other·D
Director, 10% Owner
$66.4K
44.3K sh · $1.50 avg · 2 lots
Own -100%
-
Grant·A
Director, 10% Owner
$111.5K
74.3K sh · $1.50 avg · 3 lots
Own New
-
Grant·A
Director,TenPercentOwner
$111.5K
74.3K sh · $1.50 avg · 6 lots
Own New
-
Other·F
CEO/CFO
$50.0K
25.4K sh · $1.97
Own -1%
-
Exercise·M
CEO/CFO
$50.0K
125.0K sh · $0.40
Own +6%
-
Exercise·M
Director
$0
68.8K sh
Own New
-
Exercise·M
Director
$27.5K
68.8K sh · $0.40
Own +58%
-
Other·F
Director
$27.5K
13.8K sh · $2.00
Own -7%
-
Other·F
Director
$20.0K
9.1K sh · $2.20
Own -8%
-
Exercise·M
Director
$20.0K
50.0K sh · $0.40
Own +74%
-
Exercise·M
Director
$20.0K
50.0K sh · $0.40
Own +74%
-
Other·F
Director
$20.0K
9.1K sh · $2.20
Own -8%
-
Sell·S
CEO/CFO
$300.0K
200.0K sh · $1.50
Own -9%
-
Exercise·M
Director
$35.0K
87.5K sh · $0.40
Own New
-
Other·F
Director
$35.0K
20.1K sh · $1.74
Own -23%
-
Exercise·M
Director
$48.1K
120.3K sh · $0.40
Own +481%
-
Other·F
Director
$48.1K
27.7K sh · $1.74
Own -19%
-
Exercise·M
CEO/CFO
$77.1K
192.7K sh · $0.40 avg · 2 lots
Own +10%
-
Other·F
CEO/CFO
$37.1K
21.3K sh · $1.74
Own -1%
-
Other·F
Director
$48.1K
27.7K sh · $1.74
Own -19%
-
Exercise·M
Director
$48.1K
120.3K sh · $0.40
Own +481%
-
Exercise·M
CSO/COO
$73.5K
183.9K sh · $0.40
Own +31%
-
Buy·P
TenPercentOwner
$200.0K
133.3K sh · $1.50
Own +1%
-
Grant·A
Director,TenPercentOwner
$5.9K
3.9K sh · $1.50
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | JORDEN DAVID EMERSON KEY | Grant A | 13.2K | $14.5K |
| May 29, 2026 | Pittman Scott M. | Grant A | 42.3K3 lots | $63.4K |
| May 29, 2026 | Pittman Scott M. | Other D | 44.3K2 lots | $66.4K |
| Jan 23, 2026 | Pittman Scott M. | Grant A | 74.3K3 lots | $111.5K |
| Jan 23, 2026 | Pittman Scott M. | Grant A | 74.3K6 lots | $111.5K |
| Jan 1, 2026 | JORDEN DAVID EMERSON KEY | Other F | 25.4K | $50.0K |
| Jan 1, 2026 | JORDEN DAVID EMERSON KEY | Exercise M | 125.0K | $50.0K |
| Dec 31, 2025 | WINZER C ERIC | Exercise M | 68.8K | $0 |
| Dec 17, 2025 | WINZER C ERIC | Exercise M | 68.8K | $27.5K |
| Dec 17, 2025 | WINZER C ERIC | Other F | 13.8K | $27.5K |
| Dec 9, 2025 | Mintz Paul | Other F | 9.1K | $20.0K |
| Dec 9, 2025 | Mintz Paul | Exercise M | 50.0K | $20.0K |
| Dec 9, 2025 | Mintz Paul | Exercise M | 50.0K | $20.0K |
| Dec 9, 2025 | Mintz Paul | Other F | 9.1K | $20.0K |
| Nov 28, 2025 | JORDEN DAVID EMERSON KEY | Sell S | 200.0K | $300.0K |
| Aug 1, 2025 | Mintz Paul | Exercise M | 87.5K | $35.0K |
| Aug 1, 2025 | Mintz Paul | Other F | 20.1K | $35.0K |
| Aug 1, 2025 | WINZER C ERIC | Exercise M | 120.3K | $48.1K |
| Aug 1, 2025 | WINZER C ERIC | Other F | 27.7K | $48.1K |
| Aug 1, 2025 | JORDEN DAVID EMERSON KEY | Exercise M | 192.7K2 lots | $77.1K |
| Aug 1, 2025 | JORDEN DAVID EMERSON KEY | Other F | 21.3K | $37.1K |
| Aug 1, 2025 | WINZER C ERIC | Other F | 27.7K | $48.1K |
| Aug 1, 2025 | WINZER C ERIC | Exercise M | 120.3K | $48.1K |
| Jul 31, 2025 | CLAUSEN PETER | Exercise M | 183.9K | $73.5K |
| Jul 30, 2025 | SHEEDY CHARLES E | Buy P | 133.3K | $200.0K |
| Jul 30, 2025 | Pittman Scott M. | Grant A | 3.9K | $5.9K |
Buy Sell Non-market (grant · exercise · gift)
About AURX insider trading
This page tracks insider transactions for Nuo Therapeutics, Inc. (AURX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.